EPCORITAMAB, RITUXIMAB
DS3790-076
Phase 2 small_molecule active
Quick answer
EPCORITAMAB, RITUXIMAB for Hematological Malignancies is a Phase 2 program (small_molecule) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Daiichi Sankyo Europe GmbH
- Indication
- Hematological Malignancies
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active